

**Endonovo Therapeutics, Inc**  
6320 Canoga Ave 15th Floor  
Woodland Hills, CA 91367

877-796-1456  
www.endonovo.com  
sbarnes@endonovo.com

## Annual Report

For the period ending December 31, 2025 (the “Reporting Period”)

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

1,807,556,313 as of 3/25/2026 *(Current Reporting Period Date or More Recent Date)*

1,807,556,313 as of 12/31/2025 *(Most Recent Completed Fiscal Year End)*

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period: Yes:

No:

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>5</sup> of the company has occurred during this reporting period:

Yes:  No:

---

<sup>5</sup> “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Endonovo Therapeutics, Inc

Current State and Date of Incorporation or Registration: Delaware, November 2008 Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years: None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

We have initiated the final steps leading to a spin-off of our medical SofPulse® business, SofPulse, Inc., a Delaware corporation, during the past fiscal year and will maintain a partial ownership.

Address of the issuer's principal executive office:

6320 Canoga Ave 15<sup>th</sup> Floor Woodland Hills, CA 91367

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

6320 Canoga Ave 15<sup>th</sup> Floor Woodland Hills, CA 91367

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

N/A

**2) Security Information**

**Transfer Agent**

Name: Vinyl Equity, Inc  
Phone: 778-512-2131  
Email: operations@vinylequity.com  
Address: 912 Cherry Street, Winnetka, IL 60093

**Publicly Quoted or Traded Securities:**

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>ENDV</u>
Exact title and class of securities outstanding:	<u>Common</u>
CUSIP:	<u>29272H300</u>
Par or stated value:	<u>\$.0001</u>
Total shares authorized:	<u>2,500,000,000 as of date: 3/25/2026</u>
Total shares outstanding:	<u>1,807,556,313 as of date: 3/25/2026</u>
Total number of shareholders of record:	<u>427 as of date: 3/25/2026</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

None

**Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	Preferred Stock – Series AA Super-Voting Preferred Par or
stated value:	.001
Total shares authorized:	<u>1,000,000 as of date: 3/25/2026</u>
Total shares outstanding:	<u>25,000 as of date: 3/25/2026</u>
Total number of shareholders of record:	<u>1 as of date: 3/25/2026</u>

Exact title and class of the security:	Series B Convertible Preferred Stock Par
or stated value: .	.0001
Total shares authorized:	<u>50,000 as of date: 3/25/2026</u>
Total shares outstanding:	<u>600 as of date: 3/25/2026</u>
Total number of shareholders of record:	<u>4 as of date: 3/25/2026</u>

Exact title and class of the security:	Series C Convertible Redeemable Preferred Stock
Par or stated value:	.0001
Total shares authorized:	<u>20,000 as of date: 3/25/2026</u>
Total shares outstanding:	<u>0 as of date: 3/25/2026</u>
Total number of shareholders of record:	<u>0 as of date: 3/25/2026</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

None

**Security Description:**

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

None

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

None

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

### 3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.*

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> :		*Right-click the rows below and select "Insert" to add rows as needed.							
Date <u>01/01/2023</u>	Common: 213,226,730 Preferred: <u>26,338</u>								
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to.  ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

1/3/23	<u>New Issue</u>	2,000,000	<u>Common Shares</u>	0.0018	<u>NO</u>	<u>Shane Leupold</u>	<u>Consulting Agreement</u>	<u>Restricted</u>	144
1/3/23	<u>New Issue</u>	1,000,000	<u>Common Shares</u>	0.0018	<u>NO</u>	<u>John Koziol</u>	<u>Consulting Agreement</u>	<u>Restricted</u>	144
1/3/23	<u>New Issue</u>	3,500,000	<u>Common Shares</u>	0.0018	<u>NO</u>	<u>Cornerstone Marketing, Inc Jeff Lien</u>	<u>Consulting Agreement</u>	<u>Restricted</u>	144
1/17/23	<u>New Issue</u>	5,000,000	<u>Common Shares</u>	0.017	<u>NO</u>	<u>John Jones</u>	<u>Stock Purchase Agreement</u>	<u>Restricted</u>	144
1/24/23	<u>New Issue</u>	10,000,000	<u>Common Shares</u>	0.015	<u>NO</u>	<u>Robert Nicoletta</u>	<u>Debt Conversion</u>	<u>Restricted</u>	144
2/2/23	<u>New Issue</u>	2,500,000	<u>Common Shares</u>	0.0165	<u>NO</u>	<u>Clifford Miller</u>	<u>Stock Purchase Agreement</u>	<u>Restricted</u>	144
2/6/23	<u>New Issue</u>	1,507,277	<u>Common Shares</u>	0.0165	<u>NO</u>	<u>Jefferson Street Capital, LLC Brian Goldberg</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
2/7/23	<u>New Issue</u>	5,000,000	<u>Common Shares</u>	0.008	<u>NO</u>	<u>Lawrence Block</u>	<u>Preferred D Conversion</u>	<u>Restricted</u>	144
2/16/23	<u>New Issue</u>	4,300,590	<u>Common Shares</u>	0.0156	<u>NO</u>	<u>BHP Capital NY, Inc Bryan Pantofel</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
2/27/23	<u>New Issue</u>	900,000	<u>Common Shares</u>	0.015	<u>NO</u>	<u>Robert Nicoletta</u>	<u>Debt Conversion</u>	<u>Restricted</u>	144
3/22/23	<u>New Issue</u>	10,000,000	<u>Common Shares</u>	0.014	<u>NO</u>	<u>John Jones</u>	<u>Stock Purchase Agreement</u>	<u>Restricted</u>	144
3/27/23	<u>New Issue</u>	5,000,000	<u>Common Shares</u>	0.0145	<u>NO</u>	<u>Harry Feinberg</u>	<u>Stock Purchase Agreement</u>	<u>Restricted</u>	144
4/13/23	<u>New Issue</u>	20,000,000	<u>Common Shares</u>	0.0141	<u>NO</u>	<u>Blue Ridge Consulting, LLC Alan Collier</u>	<u>Company Grant</u>	<u>Restricted</u>	144
4/13/23	<u>New Issue</u>	4,800,000	<u>Common Shares</u>	0.0141	<u>NO</u>	<u>Frank Hariton</u>	<u>Company Grant</u>	<u>Restricted</u>	144
4/13/23	<u>New Issue</u>	4,800,000	<u>Common Shares</u>	0.0141	<u>NO</u>	<u>Steven Barnes</u>	<u>Company Grant</u>	<u>Restricted</u>	144
4/21/23	<u>New Issue</u>	4,800,000	<u>Common Shares</u>	0.0159	<u>NO</u>	<u>Todd Witherspoon</u>	<u>Company Grant</u>	<u>Restricted</u>	144
5/11/23	<u>New Issue</u>	1,667,000	<u>Common Shares</u>	0.0146	<u>NO</u>	<u>Jefferson Street Capital, LLC Brian Goldberg</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
5/19/23	<u>New Issue</u>	350,000	<u>Common Shares</u>	0.0172	<u>NO</u>	<u>K. Tucker Andersen</u>	<u>Stock Purchase Agreement</u>	<u>Restricted</u>	144
6/12/23	<u>New Issue</u>	500,000	<u>Common Shares</u>	0.014	<u>NO</u>	<u>John Jones</u>	<u>Stock Purchase Agreement</u>	<u>Restricted</u>	144
7/3/23	<u>New Issue</u>	1,000,000	<u>Common Shares</u>	0.0145	<u>NO</u>	<u>Barbara Kamienski</u>	<u>Stock Purchase Agreement</u>	<u>Restricted</u>	144
7/14/23	<u>New Issue</u>	8,000,000	<u>Common Shares</u>	0.0138	<u>NO</u>	<u>FMW Media Works, LLC Vince Caruso</u>	<u>Production Agreement</u>	<u>Restricted</u>	144
8/16/23	<u>New Issue</u>	250,000	<u>Common Shares</u>	0.0095	<u>NO</u>	<u>John Jones</u>	<u>Note Extension</u>	<u>Restricted</u>	144
8/16/23	<u>New Issue</u>	250,000	<u>Common Shares</u>	0.0095	<u>NO</u>	<u>Barbara Kamienski</u>	<u>Note Extension</u>	<u>Restricted</u>	144
9/21/23	<u>New Issue</u>	250,000	<u>Common Shares</u>	0.0105	<u>NO</u>	<u>John Jones</u>	<u>Note Extension</u>	<u>Restricted</u>	144
9/21/23	<u>New Issue</u>	250,000	<u>Common Shares</u>	0.0105	<u>NO</u>	<u>Barbara Kamienski</u>	<u>Note Extension</u>	<u>Restricted</u>	144
10/2/23	<u>New Issue</u>	250,000	<u>Common</u>	0.0121	<u>NO</u>	<u>Barbara Kamienski</u>	<u>Note Extension</u>	<u>Restricted</u>	144

			Shares						
10/17/23	<u>New Issue</u>	250,000	Common Shares	0.012	NO	John Jones	Note Extension	Restricted	144
3/8/24	<u>New Issue</u>	14,286,610	Common Shares	0.00105	YES	Trillium Partners LLP – Steven Hicks	Debt Conversion	Restricted	144
4/15/24	<u>New Issue</u>	16,356,150	Common Shares	0.00105	YES	Stephen Hicks - Trillium Partners LLP	Debt Conversion	Restricted	144
5/15/24	<u>New Issue</u>	25,875,613	Common Shares	0.0008	YES	Stephen Hicks - Trillium Partners LLP	Debt Conversion	Restricted	144
5/16/25	<u>New Issue</u>	875,000	Common Shares	0.0095	NO	Barbara Kamienski	Note Extension	Restricted	144
5/16/25	<u>New Issue</u>	875,000	Common Shares	0.0095	NO	John Jones	Note Extension	Restricted	144
6/12/24	<u>New Issue</u>	19,807,975	Common Shares	0.0004	YES	Stephen Hicks - Trillium Partners LLP	Debt Conversion	Restricted	144
11/13/24	<u>New Issue</u>	16,668,511	Common Shares	0.00045	YES	Stephen Hicks - Trillium Partners LLP	Debt Conversion	Restricted	144
11/21/24	<u>New Issue</u>	39,212,857	Common Shares	0.00035	YES	Stephen Hicks - Trillium Partners LLP	Debt Conversion	Restricted	144
11/28/24	<u>New Issue</u>	15,827,000	Common Shares	0.0035	YES	Stephen Hicks - Trillium Partners LLP	Debt Conversion	Restricted	144
12/16/24	<u>New Issue</u>	28,950,000	Common Shares	0.0002	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
12/19/24	<u>New Issue</u>	17,392,000	Common Shares	0.0002	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
12/19/24	<u>New Issue</u>	28,993,000	Common Shares	0.0003	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
1/6/25	<u>New Issue</u>	32,034,000	Common Shares	0.0002	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
1/7/25	<u>New Issue</u>	53,842,000	Common Shares	0.0004	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
1/14/25	<u>New Issue</u>	35,001,000	Common Shares	0.00015	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
1/17/25	<u>New Issue</u>	62,344,000	Common Shares	0.00015	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
1/28/25	<u>New Issue</u>	54,647,000	Common Shares	0.00015	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
2/6/25	<u>New Issue</u>	71,981,000	Common Shares	0.0001	YES	Stephen Hicks - Trillium Partners LLP	Settlement Agreement	Restricted	144
2/13/25	<u>New Issue</u>	84,517,000	Common Shares	0.0001	YES	Stephen Hicks - Trillium Partners	Settlement Agreement	Restricted	144

						<u>LLP</u>			
2/25/25	<u>New Issue</u>	92,884,000	<u>Common Shares</u>	0.0001	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
2/28/25	<u>New Issue</u>	66,800,000	<u>Common Shares</u>	0.00005	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
3/11/25	<u>New Issue</u>	108,693,000	<u>Common Shares</u>	0.00005	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
7/18/25	<u>New Issue</u>	119,453,000	<u>Common Shares</u>	0.00004	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
8/6/25	<u>New Issue</u>	119,646,000	<u>Common Shares</u>	0.00004	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
8/21/25	<u>New Issue</u>	120,540,000	<u>Common Shares</u>	0.0001	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
8/27/25	<u>New Issue</u>	120,651,000	<u>Common Shares</u>	0.0001	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144
9/4/25	<u>New Issue</u>	120,652,000	<u>Common Shares</u>	0.0001	<u>YES</u>	<u>Stephen Hicks - Trillium Partners LLP</u>	<u>Settlement Agreement</u>	<u>Restricted</u>	144

Shares Outstanding on Date of This Report:	
<u>Ending Balance:</u>	
Date: <u>3/25/2026</u>	Common: <u>1,807,556.313</u>
	Preferred: <u>26,338</u>

**Example:** A company with a fiscal year end of December 31<sup>st</sup> 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

None

## B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Any additional material details, including footnotes to the table are below:

NA

## Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Endonovo Therapeutics, Inc. (Endonovo or the "Company") is an innovative biotechnology company that has developed a bio-electronic non-invasive and drug-free approach to regenerative medicine.

The Company develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body. The company has already received FDA clearance for SofPulse® for the reduction of pain and edema postoperatively. Additionally, the Company's non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, central nervous system disorders ("CNS" disorders) including Multiple Sclerosis (MS), Traumatic Brain Injury (TBI), Dementia, Alzheimer's, and Ischemic stroke among others.

Endonovo's core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company's Electroceutical® Therapy. Endonovo's bioelectric Electroceutical® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

In December 2022 the Company brought in new management in order to re-initiate the domestic sales of SofPulse® and further develop its international global market as well. As part of the reorganization of company management, the company is in the process of expanding their distribution and sales networks to include the development of a robust telemedicine (telehealth) platform expansion efforts for their medical devices.

We have initiated the final steps leading a spin off of our medical SofPulse® business through a public offering by our subsidiary SofPulse, Inc. We will retain the tele-health, non-medical and wellness SofPulse® rights and receive shares in SofPulse, Inc., the majority of which will be paid as a dividend to our shareholders pro-rata in an offering registered under the Securities Act of 1933, as amended. While we anticipate that this will be completed during the current year, we can give no assurances as to when or if this spin-off will be completed.

B. List any subsidiaries, parent company, or affiliated companies.

Subsidiary: IP Resources International, Inc.

Subsidiary: WeHealAnimals, Inc.

Subsidiary: Aviva Companies Corporation

Affiliated Company: SofPulse, Inc.

C. Describe the issuers' principal products or services.

We are currently a biotechnology company developing bioelectronic devices and cell therapies for regenerative medicine and a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices.

The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using

pulsed short-wave radiofrequency at 27.12 MHz has been FDA- Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease.

(PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

These bioelectronics devices are also commonly referred to as "electroceuticals." These products are part of an emerging field termed "Bioelectronic Medicine," that seeks to harness electrical signals in nerves and cells to alter the course of diseases and conditions. Whereas our competitors are primarily using implantable electrical nerve stimulators, we are developing devices that are not implantable and use electromagnetic pulses to deliver electrical stimulation to cells and tissues. We are developing these bioelectronic devices for the treatment of inflammatory conditions in tissues and vital organs with a concentration on vascular diseases and ischemia/reperfusion injuries.

The Company is negotiating with a major distribution partner in order to initiate the marketing of SofPulse® in South and Central America. Additionally, the Company is currently engaged in distribution discussions with recognized distribution partners in Australia, Europe, and various Southeast Asian markets. SofPulse® has received regulatory clearance in Taiwan through Endonovo's distribution partner Evermed Medical Enterprise, Ltd. in the second half of 2023.

device proven to reduce opioid use. This initiative is in the early stages and has not to date generated revenue.

## Issuer's Facilities

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

We have a virtual office at 6320 Canoga Avenue, 15<sup>th</sup> Floor, Woodland Hills, California 91367 and no other facilities. All of our assets are intangible which are our intellectual Property and Trademarks except for our inventory which resides at ADM Tronics Unlimited, Inc. 224 Pegasus Avenue, Northvale NJ 0764 7 USA

## All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
<u>Alan Collier(1)</u>	<u>Officer/Director</u>	<u>Woodland Hills, California</u>	<u>45,026,212</u> <u>25,000</u>	<u>Common</u> <u>Preferred -</u> <u>Super</u> <u>Voting</u>	<u>2.49%</u> <u>100%</u>

(1) Shares owned and/or controlled by Mr. Collier

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

On 05/26/2023 a Stipulated judgment for attorney’s fees and costs was entered against us for, attorney fees and cost for a total of \$256,850.65. This judgment has been assigned to Trillium Partners and is no longer a liability of the Company.

As of April 18, 2024, the Company was sued by a consultant under a consulting agreement for unpaid consulting fees in the amount of \$87,000.00, plus interest of \$39,258.74

**8) Third Party Service Providers**

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name:	<u>Frank Hariton</u>
Address 1:	1065 Dobbs Ferry Rd
Address 2:	White Plains NY 10607
Phone:	<u>914-674-4373</u>
Email:	<u>hariton@sprynet.com</u>

Accountant or Auditor

Name:	_____
Firm:	_____
Address 1:	_____
Address 2:	_____
Phone:	_____
Email:	_____

Investor Relations

Name:	_____
Firm:	_____
Address 1:	_____
Address 2:	_____
Phone:	_____
Email:	_____

*All other means of Investor Communication:*

X (Twitter):	_____
Discord:	_____
LinkedIn	_____
Facebook:	_____
[Other ]	_____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Ali Shan Aslam  
Firm: The Pro Advisory  
Nature of Services: Accounting & Financial Services  
Address 1: Remotely Operating in USA  
Address 2:  
Phone: +971 50 153 5083  
Email: [ali@theproadvisory.com](mailto:ali@theproadvisory.com)

## 9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Alan Collier  
Title: CEO  
Relationship to Issuer: Affiliate, Officer and Director

B. The following financial statements were prepared in accordance with:

IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Ali Shan Aslam  
Title: Chartered Accountant (ACA)  
Relationship to Issuer: Consultant

Describe the qualifications of the person or persons who prepared the financial statements:<sup>7</sup>  
Ali Shan has an experience of over 10 years as CFO of different companies.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- Financial Notes

### **Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable.” Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.

<sup>7</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- 
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

**ENDONOVO THERAPEUTICS, INC.**  
INDEX TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

	Pages
Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024	F-1
Consolidated Statements of Operations for the years ended December 31, 2025 and 2024	F-2
Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024	F-3
Consolidated Statements of Changes in Stockholders' Equity (Deficit)	F-4
Notes to Consolidated Financial Statements	F-5

**Endonovo Therapeutics, Inc. and Subsidiaries**  
**Consolidated Balance Sheets**

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
<b>ASSETS</b>		
Current Assets:		
Cash	\$ 12	\$ 3
Accounts receivable, net	-	-
Prepaid expenses and other current assets	17,718	17,716
Total current assets	<u>17,730</u>	<u>17,719</u>
Patents, net	-	-
Total assets	<u>\$ 17,730</u>	<u>\$ 17,719</u>
<b>LIABILITIES AND SHAREHOLDERS' DEFICIT</b>		
Current Liabilities		
Accounts payable and accrued liabilities	\$ 3,324,872	\$ 3,429,811
Accrued interest	7,076,617	5,839,253
Deferred compensation	5,160,904	4,266,904
Notes payable, net of discounts of \$0 and \$4,822 at December 31, 2025 and 2024 respectively	6,821,459	6,777,069
Notes payable – former related party	92,550	92,550
Derivative liability	6,336,686	6,336,686
Total current liabilities	<u>28,813,088</u>	<u>26,742,273</u>
Other long-term liabilities	79,825	79,825
Total liabilities	<u>28,892,913</u>	<u>26,822,098</u>
COMMITMENTS AND CONTINGENCIES, note 8		
Shareholders' deficit		
Super AA super voting preferred stock, \$0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding as of December 31, 2025 and 2024	25	25
Series B convertible preferred stock, \$0.0001 par value; 50,000 shares authorized and 600 issued and outstanding as of December 31, 2025 and 2024	1	1
Series C convertible preferred stock, \$0.0001 par value, 8,000 shares authorized, 738 shares issued and outstanding as of December 31, 2025 and 2024	-	-
Series D convertible preferred stock, \$0.0001 par value; 20,000 shares authorized and 0 issued and outstanding as of December 31, 2025 and 2024	-	-
Common stock, \$0.0001 par value; 2,500,000,000 shares authorized; 1,807,556,313 and 543,871,313 shares issued and outstanding as of December 31, 2025 and 2024, respectively	168,672	54,370
Additional paid-in capital	44,164,739	44,174,080
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	<u>(73,207,049)</u>	<u>(71,031,284)</u>

Total shareholders' deficit	(28,875,183)	(26,804,376)
Total liabilities and shareholders' deficit	<u>\$ 17,730</u>	<u>\$ 17,719</u>

*See accompanying summary of accounting policies and notes to consolidated financial statements.*

**Endonovo Therapeutics, Inc. and Subsidiaries**  
**Consolidated Statements of Operations**  
**For the year ended December 31,**

	2025	2024
Revenue	\$ -	\$ 10,043
Cost of revenue	-	(6,709)
Gross profit	-	3,335
Operating expenses	(945,766)	(1,563,267)
Loss from operations	(945,766)	(1,559,933)
Other income (expense)		
Change in fair value of derivative liability	-	-
Gain on extinguishment of debt	7,000	-
Other expense	-	-
Interest expense, net	(1,237,634)	(1,237,634)
Total other expense	(1,230,364)	(1,237,634)
Gain / (loss) before income taxes	(2,176,130)	(2,797,297)
Provision for income taxes	-	-
Net Gain / (loss)	\$ (2,176,130)	(2,797,297)
Basic Gain / (loss) per share	\$ (0.00)	\$ (0.00)
Diluted Gain / (loss) per share	(0.00)	(0.00)

*See accompanying summary of accounting policies and notes to consolidated financial statements*

**Endonovo Therapeutics, Inc. and Subsidiaries**  
**Consolidated Statement of Shareholders' Deficit**  
**For the years ended December 31, 2025 and 2024**

*For The Year Ended December 31, 2024*

	Series AA		Series B Convertible		Series D Convertible		Series C Convertible		Common Stock		Additional		Total	
	Preferred Stock		Preferred Stock		Preferred Stock		Preferred Stock		Common Stock		Paid-in	Subscription	Accumulated	Shareholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Receivable	Deficit	Deficit
Balance December 31, 2023	25,000	\$ 25	600	\$ 1	-	-	-	-	320,427,538	32,542	44,095,049	(1,570)	(68,233,987)	(24,107,941)
Issuance of shares for loan extension	-	-	-	-	-	-	-	-	1,750,000	175	-	-	-	175
Common Stock issued for cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued for conversion of notes payable and accrued interest	-	-	-	-	-	-	-	-	(148,034,716)	(14,803)	(122,615)	-	-	(137,418)
Common Stock issued for Debt Settlement	-	-	-	-	-	-	-	-	(75,335,000)	(7,533)	(10,433)	-	-	(17,966)
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	(2,797,297)	(2,797,297)
Balance December 31, 2024	25,000	\$ 25	600	\$ 1	-	-	-	-	543,871,313	54,370	44,174,080	(1,570)	(71,031,284)	(26,804,376)

*For The Year Ended December 31, 2025*

	Series AA		Series B Convertible		Series D Convertible		Series C Convertible		Common Stock		Additional		Total	
	Preferred Stock		Preferred Stock		Preferred Stock		Preferred Stock		Common Stock		Paid-in	Subscription	Accumulated	Shareholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Receivable	Deficit	Deficit
Balance December 31, 2024	25,000	\$ 25	600	\$ 1	-	-	-	-	543,871,313	54,370	44,174,080	(1,570)	(71,031,284)	(26,804,376)
Issuance of shares for loan extension	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock issued for cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued for conversion of notes payable and accrued interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock issued for Debt Settlement	-	-	-	-	-	-	-	-	1,263,685,000	126,369	(9,341)	-	-	117,027
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	(2,176,130)	(2,176,130)
Balance September 30, 2025	25,000	\$ 25	600	\$ 1	-	-	-	-	1,807,556,313	168,672	44,164,739	(1,570)	(73,207,049)	(28,875,183)

*See accompanying summary of accounting policies and notes to consolidated financial statements.*

**Endonovo Therapeutics, Inc. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
**For the years ended December 31,**

□

	2025	8	2024
<b>Operating activities:</b>			
Net (Loss) / Gain	\$	(2,176,130)	\$ (2,797,297)
<b>Adjustments to reconcile net loss to cash used in operating activities:</b>			
Depreciation and amortization expense		-	618,532
Bad debt expense		-	-
Stock-based compensation		-	-
Fair value of commitment shares issued with debt		-	-
Fair value of equity issued for services		-	-
Amortization of note discount and original issue discount		-	-
Change in fair value of derivative liability		-	-
Gain on extinguishment of debt		7,000	-
<b>Changes in assets and liabilities:</b>			
Prepaid expenses and other current assets		-	-
Accounts payable and accrued liabilities		(5,226)	2,347,173
Accrued interest		1,237,364	1,082,297
Deferred compensation		894,000	(1,150,218)
<b>Net cash used in operating activities</b>		<b>(42,991)</b>	<b>100,487</b>
<b>Financing activities:</b>			
Proceeds or (Repayment) of notes payable		43,000	(203,191)
Repayments on former related party advances		-	-
Proceeds from issuance of common stock and units		-	97,859
Repayment of convertible debt in cash		-	-
<b>Net cash provided by financing activities</b>		<b>43,000</b>	<b>(105,332)</b>
<b>Net increase (decrease) in cash</b>		<b>9</b>	<b>(1,835)</b>
Cash, beginning of year		(3)	1,838
<b>Cash, end of year</b>	<b>\$</b>	<b>12</b>	<b>\$ 3</b>

*See accompanying summary of accounting policies and notes to consolidated financial statements.*

**Endonovo Therapeutics, Inc. and  
Subsidiary Notes to Consolidated  
Financial Statements  
For the Years Ended December 31, 2025 and 2024**

**Note 1 - Nature of Business and Summary of Significant Accounting Policies**

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of inflammation on and in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical® Therapy. Endonovo’s bioelectric Electroceutical® devices harnesses *bioelectricity* to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.

*Basis of Presentation and Principles of Consolidation*

The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc.. All significant intercompany accounts and transactions are eliminated in consolidation.

*Going Concern*

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has accumulated losses of \$72.6 million, negative cash flows from operations and \$28.3 million of shareholder deficit. The Company is raising additional capital through debt and/or equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is implementing its new business plan, has raised capital through the issuance of promissory notes and is engaging a broker/dealer to raise additional capital.

*Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services and in connection with notes payable agreements, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates

*Cash and cash equivalents*

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2025 and 2024, the Company does not hold any cash in excess of FDIC limits and does not have any cash equivalents.

#### *Accounts Receivable*

The Company uses the specific identification method for recording the provision for doubtful accounts, which was \$0 at December 31, 2025 and 2024. Account receivables are written off when all collection attempts have failed.

#### *Impairment of Long-lived Assets*

The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value. The Company did not recognize any impairment loss during the periods ended December 31, 2025 and 2024.

#### *Equity-Based Compensation*

The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method.

#### *Income Taxes*

The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.

#### *Net Loss per Share*

Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.

The Company has 6,011,750 stock options, of which 3,013,070 and 2,013,070 are exercisable respectively and 2,000 warrants convertible into an equivalent number of common stock as of December 31, 2025 and 2024.

As of December 31, 2025 and 2024, the Company has variable rate convertible notes in an aggregate amount of \$4,300,590 and \$4,300,590, respectively. Such shares are not included in the calculation of the diluted net loss per share as they would have an antidilutive effect.

## Fair Value of Financial Instruments

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The Company's balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company's recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operation.

The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2025 and 2024:

Fair Value Measurements at December 31, 2025 Using

	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
Derivative liability	\$ -	\$ -	\$ 6,336,686	\$ 6,336,686
Total	\$ -	\$ -	\$ 6,336,686	\$ 6,336,686

Fair Value Measurements at December 31, 2024 Using

	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
Derivative liability	\$ -	\$ -	\$ 6,336,686	\$6,336,686
Total	\$ -	\$ -	\$ 6,336,686	\$6,336,686

The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2025, 2024, 2023 and 2022:

	Derivative Liability
Balance December 31, 2022	\$ 17,359,064
Settlement by debt Extinguishment	(10,769)
Change in estimated fair value	(11,011,609)
Balance December 31, 2023	\$ 6,336,686
Settlement by debt Extinguishment	-
Change in estimated fair value	-
Balance December 31, 2024	\$ 6,336,686
Settlement by debt Extinguishment	-
Change in estimated fair value	-
Balance December 30, 2025	\$ 6,336,686

As of December 31, 2025 and 2024, the Company has variable rate convertible promissory notes, which contained variable conversion rates based on unknown future prices of the Company's common stock. This resulted in the recognition of a derivative liability as the conversion feature failed the scope exception for derivative accounting due to the variability of its conversion price. The Company continues to measure the derivative liability using the Black-Scholes option valuation model 2022.

The assumptions used in determining fair value represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. As a result, if factors change, including changes in the market value of the Company's common stock, managements' assessment, or significant fluctuations in the volatility of the trading market for the Company's common stock, the Company's fair value estimates could be materially different in the future.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company's stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company's Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

#### *Recent Accounting Standard Updates*

**The Company has evaluated all the recent accounting pronouncements and determined that there are no accounting pronouncements that will have a material effect on the Company's financial statements.**

#### **Note 2 - Revenue Recognition**

## **Contracts with Customers**

We have adopted ASC 606, *Revenue from Contracts with Customers* effective January 1, 2018, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer's contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, we have an unconditional right to receive payment. Our sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.

Revenues for sales of our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.

In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

- During the year ended December 31, 2025 and 2024, we recognized revenue of \$0 and \$10,043, respectively, from SofPulse® devices. In 2024, this revenue from SofPulse® devices has been transferred to SofPulse, Inc. pursuant to the Asset Purchase Agreement dated December 2023 between the two companies.

## **Sources of Revenue**

For the years ended December 31, 2025 and 2024, our revenue was \$0 and \$10,043.

In accordance with our Press Release dated December 4, 2024 and we are in the process of completing our initial Digital Healthcare site and, we believe revenues should be commencing in near future from this development, the tele-health contract with SofPulse, Inc. and our other products.

## ***Warranty***

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

## **Significant Judgments in the Application of the Guidance in ASC 606**

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

## ***Practical Expedients***

Our payment terms for sales direct to distributors, end users, hospitals and doctors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

### ***Effective Date and Transition Disclosures***

Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

### **Note 3 – Patents**

In December 2017, we acquired from RGN a patent portfolio for \$4,500,000. As of December 31, 2025 and 2024, pursuant to the accumulated amortization schedule the net value of the patents is \$0.

### **Note 4 - Notes payable**

As of December 31, 2025 and 2024, the notes payable activity was as follows:

Notes payable at beginning of period	\$ 6,874,441	\$ 7,077,632
Notes payable issued	39,568	-
Settlements on note payable	-	-
Repayments of notes payable in cash	-	(56,602)
Less amounts converted to stock	-	(146,589)
<b>Notes payable at end of period</b>	<b>6,914,009</b>	<b>6,874,441</b>
Less debt discount	-	(4,822)
	<u>\$ 6,914,009</u>	<u>\$ 6,869,619</u>
Notes payable issued to former related party	\$ 92,550	\$ 92,550
Notes payable issued to non-related party	\$ 6,821,459	\$ 6,777,069

### ***Activity during the year ended December 31, 2025***

#### *Fixed rates convertible notes*

During the year ended December 31, 2025, the Company issued four (4) fixed rate promissory notes.

As of December 31, 2025 the Company has twenty-seven (27) fixed-rate promissory notes with an outstanding balance of \$1,735,350.

As of December 31, 2025, the Company has a total of eighteen (18) fixed rate notes for total principal amount of \$1,293,411 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18%.

### ***Activity during the year ended December 31, 2024***

During the year ended December 31, 2024, the Company did not issue any fixed rate promissory notes.

As of December 31, 2024, the Company has twenty (23) fixed-rate promissory notes with an outstanding balance of \$1,690,961. As of December 31, 2024, the Company has a total of eighteen (18) fixed rate notes for total principal amount of \$1,293,411 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares.

#### *Variable-rate notes*

During the year ended December 31, 2024, the Company executed a settlement agreement with one investor to extinguish the remaining principal balance of a promissory note into 4,300,590 shares of common stock.

### **Note 5 - Shareholders' Deficit**

#### *Preferred Stock*

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

	Number of Shares Authorized	Number of Shares Outstanding at September 30, 2025	Par Value	Liquidation Value per Share
Series AA	1,000,000	25,000	\$ 0.0010	-
Preferred Series B	50,000	600	\$ 0.0001	100
Preferred Series C	8,000	738	\$ 0.0001	1,000
Preferred Series D	20,000	-	\$ 0.0001	1,000
Undesignated	3,922,000	-	-	-

#### *Series AA Preferred Shares*

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company's Articles of Incorporation, as amended (the "Articles of Incorporation"), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value \$0.001 per share, designated "Series AA Super Voting Preferred Stock," for which the board of directors established the rights, preferences and limitations thereof.

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of December 31, 2025 and 2024, there were 25,000 shares of Series AA Preferred stock outstanding.

#### *Series B Convertible Preferred Stock*

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B ("Series B") which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value (\$100 per share) divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company's issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, \$100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. There has been no activity during the year ended December 31, 2025 and 2024. As of December 31, 2025 and 2024, there were 600 shares of Series B outstanding.

### *Series C Secured Redeemable Preferred Stock*

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a \$20.00 quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, \$1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation for its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, \$1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.

Management determined the fair value of the new instrument based on the guidance in ASC 820 Fair Value Measurement. Management concluded that the preferred stock should not be classified as a liability per the guidance in ASC 480 Distinguishing Liabilities from Equity even though the conversion would require the issuance of variable number of shares since such obligation is not unconditional. Management classified the Series C in permanent equity As of December 31, 2025 and 2024, there were 738 shares of Series C outstanding.

### *Series D Convertible Preferred Stock*

On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock.

The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, \$1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.

In September 2022, the Company offered to each holder of Series D the opportunity to convert each share of Series D into 100,000 shares of the Company’s common stock at an effective conversion price of \$0.01. In addition, the Company included a make whole provision, which assures each holder a 15% return on the resale, effectively potentially granting them additional common shares until the holder realizes a 15% return upon resale.

As of December 31, 2025 and 2024, there were 0 shares of Series D outstanding.

### *Common Stock*

#### *Activity during the year ended December 31, 2025 and 2024:*

During the year ended December 31, 2025, the Company issued 1,014,586,000 shares of common stock pursuant to a settlement agreement for the payment of principal notes, deferred compensation, accrued interest and accounts payable.

During the year ended December 31, 2024, the Company issued 148,034,716 shares of common stock for the conversion of principal notes and accrued interest and issued 75,335,000 shares of common stock pursuant to a settlement agreement for the payment of principal notes, deferred compensation, accrued interest and accounts payable.

## Stock Options

During the year ended December 31, 2022, the Company executed an independent contractor agreement with the Company's new President and Chief Commercial Officer of its medical division. Pursuant to this agreement, the Company granted 3,000,000 stock options to purchase an equivalent number of common stocks, with 250,000 options vesting each quarter with a term of 2 years from vesting and a strike price of \$0.0076. As of December 31, 2025 there are 6,011,750 options at a weighted average exercise price of \$0.12 per share

## Warrants

During the year ended December 31, 2025 and 2024, the Company did not issue any warrants. A summary of the changes of the warrants during the year ended December 31, 2025 and 2024, are presented below:

	Outstanding Warrants	
	Shares	Weighted Average Exercise Price Per Share
Outstanding at December 31, 2023	2,000	\$ 50.00
Granted	-	\$ -
Cancelled	-	\$ -
Exercised	-	\$ -
Outstanding at December 31, 2024	2,000	\$ 50.00
Outstanding & Exercisable at December 31, 2025	2,000	\$ 50.00

## Note 6 – Related Party and former Related Parties Transactions

One executive officer, one former executive and one former operational manager of the Company have agreed to defer a portion of their compensation until cash flow improves. As of December 31, 2025 and 2024, the balances of their deferred compensation were \$1,490,665 and \$1,282,265, which reflects \$272,400 and \$292,500 accrual of deferred compensation in accordance with contractual arrangement during the years ended December 31, 2025 and 2024 respectively, and \$300,000 accrual of deferred compensation, \$27,600 cash repayments of deferred compensation during the year ended December 31, 2025.

During the year ended December 31, 2025 and 2024, the Company issued 0 shares of common stock to related parties.

During the year ended December 31, 2025, the Chief Executive Officer of the Company advanced \$85 of funds to the Company of which \$0 was repaid during the year 2025. During the period ended December 31, 2024, the Chief Executive Officer of the Company advanced \$0 of funds to the Company of which \$0 was repaid during the year 2024.

The balance of short-term advances due to one officer and executive of the Company at December 31, 2025 and 2024 was \$3,040 and is included in the Company's accounts payable and accrued interest balance as of December 31, 2025 and 2024.

At December 31, 2025 and 2024, notes payable remain outstanding to the former President of the Company, in the amount of \$92,550.

## Note 7 - Income taxes

The Company files income tax returns with the Internal Revenue Service ("IRS") and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years.

The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2025 and 2024, the Company had approximately \$37,600,000 and \$36,000,000 of federal net operating loss carryforwards, respectively, that it can use to offset a certain amount of taxable income in the future. Some of these federal net operating loss carryforwards begin to expire in 2030. The

resulting deferred tax asset is offset by a 100% valuation allowance due to the uncertainty of its realization. Utilization of these net operating losses could be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state laws based on ownership changes and the value of the Company’s stock.

A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2025 and 2024:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Income tax computed at federal statutory rate	-21.0%	-21.0%
State taxes, net of federal benefit	-1.7%	-1.7%
Non-Deductible expenses	15.6%	15.6%
Change in valuation allowance	7.1%	7.1%
<b>Total</b>	<b>0.0%</b>	<b>0.0%</b>

The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance.

The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled \$0 for the years ended December 31, 2025 and 2024.

## **Note 8 - Commitments and Contingencies**

### *Legal matters*

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of December 31, 2025, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity expect for the below:

On 05/26/2023 a Stipulated judgment for attorney’s fees and costs was entered against us for, attorney fees and cost for a total of \$256,850.65. This judgment has been assigned to Trillium Partners and is no longer a liability of the Company.

As of April 18, 2024, the Company was sued by a consultant under a consulting agreement for unpaid consulting fees in the amount of \$87,000.00, plus interest of \$39,258.74

## **Note 9 – Concentrations.**

### *Sales*

During the year ended December 31, 2025, the Company had no revenue.

### *Supplier*

We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.

*Accounts Receivable*

There are no accounts receivable balance as of December 31, 2025 and 2024.

**Note 10 - Subsequent Events.**

Subsequent to December 31, 2025, the Company issued two \$50,000 fixed rate promissory note at 10% interest per annum.

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Alan Collier certify that:

1. I have reviewed this Disclosure Statement for Endonovo Therapeutics, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 25, 2026

/s/ Alan Collier

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

### *Principal Financial Officer:*

I, Alan Collier certify that:

1. I have reviewed this Disclosure Statement for Endonovo Therapeutics, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 25, 2026

/s/ Alan Collier

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)